Keywords: tracleer, delays, pah, worsening, who-defined, class, ii

Tracleer delays PAH worsening in WHO-defined class II patients

Article | 10 September 2007

Print This

Swiss biotechnology firm Actelion says that data from a Phase IIIb trial of Tracleer (bosentan), in patients with mildly symptomatic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in